meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HER2-positive
es-BC - HER2 negative - (neo)adjuvant (NA)
1
es-BC - HER2 positive - (neo)adjuvant (NA)
4
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1)
5
la/mBC - HER2 positive - 2nd Line (L2)
13
antibody–drug conjugate
trastuzumab deruxtecan
trastuzumab emtansine
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib plus vinorelbine
HER2 inhibitor
neratinib based treatment
neratinib
neratinib plus capecitabine
tucatinib based treatment
tucatinib plus trastuzumab plus capecitabine
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib
lapatinib plus capecitabine
lapatinib plus trastuzumab
inetetamab plus vinorelbine
target therapy
margetuximab based treatment
margetuximab plus chemotherapy
versus all
vs antibody–drug conjugate
vs trastuzumab emtansine
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs vinca alkaloids
vs vinorelbine
vs Standard of Care (SoC)
vs HER inhibitor
vs HER2 inhibitor
vs trastuzumab based treatment
vs trastuzumab plus capecitabine
vs trastuzumab plus chemotherapy
vs trastuzumab plus vinorelbine
vs TKI anti HER1/EGFR and HER2/neu
vs lapatinib based treatment
vs lapatinib
vs lapatinib plus capecitabine
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
tucatinib based treatment
tucatinib plus trastuzumab plus capecitabine
la/mBC - HER2 positive - 2nd Line (L2)
13
Comparator:
vs trastuzumab plus capecitabine;
Risk of bias:
low;
some concerns;
high;
NA;